ArticleJournal of cardiothoracic surgery2026
What is the optimal antiplatelet therapy in patients with chronic coronary syndrome undergoing coronary artery bypass grafting?
Article in Journal of cardiothoracic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivePatients with chronic coronary syndrome (CCS) make up a large portion of those undergoing coronary artery bypass grafting (CABG), and there are significant gaps in the evidence regarding the optimal aspirin dosage after CABG and whether dual antiplatelet therapy (DAPT) should be initiated after CABG. Therefore, we aimed to address this issue.
methodsBetween January-2010 and June-2022, 1607-patients who underwent primary isolated CABG with CCS were included in the final analysis and divided into three groups according to their discharge antiplatelet treatment: patients receiving 75 mg of aspirin (n = 526), patients receiving 300 mg of aspirin (n = 825) and patients receiving DAPT consisting of aspirin 75 mg and clopidogrel 75 mg (n = 256). Three separate propensity-matched analyses were performed: aspirin 75 mg vs aspirin 300 mg, DAPT vs aspirin 75 mg and aspirin 300 mg vs DAPT. Primary endpoint was long-term incidence major adverse cardiac and cerebral events (MACCE), defined as the composite of all-cause mortality, myocardial infarction, repeat revascularization and stroke. Furthermore, 497 angiograms were retrieved at follow-up and graft patency was evaluated.
resultsIn the matched cohort, aspirin 300 mg and DAPT, compared with aspirin 75 mg at discharge, were associated with reduced incidence of MACCE (HR:0.65; 95% CI [0.48-0.86]; adjusted P = 0.009) and (HR:0.62; 95% CI [0.41-0.93]; adjusted P = 0.04), respectively. However, the incidence of MACCE was comparable between aspirin 300 mg and DAPT at follow-up (HR:0.86; 95% CI [0.55-1.33]; adjusted P = 0.50). As for the retrieved angiograms at follow-up, aspirin 300 mg and DAPT were associated with a lower incidence of any graft failure (19.2% vs. 25.8%; P = 0.009) and (14.7% vs. 25.8%; P = 0.007), respectively, compared with aspirin 75 mg. On the other hand, aspirin 300 mg and DAPT had comparable incidence of any graft failure.
conclusionsIn patients with CCS following CABG, discharge treatment with 300 mg aspirin or DAPT was associated with a lower incidence of MACCE and better graft patency than 75 mg aspirin; however, these findings should be interpreted cautiously given the observational design and potential for residual confounding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.